Brad Burge

Psychedelics and biotech company ATAI Life Sciences announced on Monday the launch of a new subsidiary that will focus on the development of MDMA derivatives for the treatment of post-traumatic stress disorder and other indications. EmpathBio will be a wholly owned subsidiary of ATAI, led by CEO...

After 34 years of work, the Multidisciplinary Association for Psychedelic Studies (MAPS) is steps away from achieving FDA approval for MDMA-assisted psychotherapy in the treatment of post-traumatic stress disorder.  This would be the first time in history a psychedelic substance is approved by...